Phase I-II Study of R11577
ID Number 12-0567-00001Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to examine the safety and effectiveness of the investigational drug, Zarnestra, when used in combination with the standard care of chemotherapy drug, Paclitaxel, in patients with locally advanced breast cancer. Zarnestra is considered an investigational drug in this research study because it has not been approved by the Food and Drug Administration (FDA).
Recruiting Patients: No